Skip to content

Our Portfolio

Selecta Biosciences, Inc.

Selecta Biosciences, developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. Selecta’s synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.